Pegfilgrastim in Children With Severe Congenital Neutropenia

被引：10

作者：

Fioredda, Francesca ^{[1
]}

Calvillo, Michaela

Lanciotti, Marina

Lanza, Tiziana

Giunti, Laura ^{[2
]}

Castagnola, Elio ^{[3
]}

Lorenzi, Ines ^{[4
]}

Tonelli, Rossella ^{[5
]}

Ghezzi, Piero ^{[5
]}

Dufour, Carlo

机构：

[1] Giannina Gaslini Childrens Hosp, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Haematol Unit, I-16147 Genoa, Italy

[2] Meyer Hosp, Dept Pediat, Med Genet Unit, Florence, Italy

[3] Giannina Gaslini Childrens Hosp, Infect Dis Unit, I-16147 Genoa, Italy

[4] Giannina Gaslini Childrens Hosp, Dept Pharm, I-16147 Genoa, Italy

[5] Mario Negri Inst Pharmacol Res, Lab Neuroimmunol, Milan, Italy

来源：

PEDIATRIC BLOOD & CANCER | 2010年 / 54卷 / 03期

关键词：

filgrastim; pegfilgrastim; r-Hu-granulocyte-stimulating factor; severe congenital neutropenia; G-CSF; FILGRASTIM;

D O I：

10.1002/pbc.22350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 clays within a Pilot Study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil Count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data Suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim. Pediatr Blood Cancer 2010;54:465-467. (C) 2009 Wiley-Liss, Inc.

引用

页码：465 / 467

页数：3

共 50 条

[31] Severe congenital neutropenia and the unfolded protein response
Xia, Jun
Link, Daniel C.
CURRENT OPINION IN HEMATOLOGY, 2008, 15 (01) : 1 - 7
[32] Severe and recurrent infections identify severe congenital neutropenia and primary immunodeficiencies in pediatric isolated neutropenia
Saettini, F.
Mantovani, P.
De Lorenzo, P.
Biondi, A.
Bonanomi, S.
CLINICAL IMMUNOLOGY, 2021, 223
[33] Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Claudio Cerchione
Davide Nappi
Giovanni Martinelli
Supportive Care in Cancer, 2021, 29 : 6973 - 6980
[34] Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Cerchione, Claudio
Nappi, Davide
Martinelli, Giovanni
SUPPORTIVE CARE IN CANCER, 2021, 29 (11) : 6973 - 6980
[35] Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
MacDonald, Karen
McBride, Ali
Alrawashdh, Neda
Abraham, Ivo
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1466 - 1476
[36] RUNX1 Mutations in the Leukemic Progression of Severe Congenital Neutropenia
Olofsen, Patricia A.
Touw, Ivo P.
MOLECULES AND CELLS, 2020, 43 (02) : 139 - 144
[37] Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia
Carlsson, G
Åhlin, A
Dahllöf, G
Elinder, G
Henter, JI
Palmblad, J
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (01) : 127 - 132
[38] Pegfilgrastim Administered Once Per Cycle Reduces Incidence of Chemotherapy-Induced Neutropenia
Jeffrey Crawford
Drugs, 2002, 62 : 89 - 98
[39] Successful orthognathic surgery in a patient with severe congenital neutropenia
Higaki, Mirai
Koizumi, Koichi
Hirota, Suguru
Yanamoto, Souichi
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY MEDICINE AND PATHOLOGY, 2023, 35 (05) : 464 - 467
[40] Hematopoietic stem cell transplantation for severe congenital neutropenia
Connelly, James A.
Choi, Sung W.
Levine, John E.
CURRENT OPINION IN HEMATOLOGY, 2012, 19 (01) : 44 - 51

← 1 2 3 4 5 →